Table 1 Number of extracted VE records of partial, full, and booster immunization for any or severe COVID-19 according to investigated predictors (including the number of studies in brackets)
Predictors | Vaccine | mRNA | AdV | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Immunization against | Any COVID-19 | Severe COVID-19 | Any COVID-19 | Severe COVID-19 | |||||||
Number of vaccine doses | 1 | 2 | 3 | 1 | 2 | 3 | 1 | 2 | 1 | 2 | |
COVID-19 | Infection | 423 (109) | 1165 (160) | 76 (14) | 91 (29) | 180 (42) | |||||
Disease | 146 (48) | 630 (69) | 50 (6) | 59 (20) | 220 (26) | ||||||
Hospitalization | 234 (50) | 791 (96) | 85 (18) | 78 (23) | 220 (38) | ||||||
Death | 51 (28) | 199 (42) | 12 (7) | 37 (17) | 104 (26) | ||||||
Study termination | Jan–Feb 2021 | 97 (24) | 61 (13) | 39 (5) | 20 (2) | 7 (3) | 13 (1) | ||||
Mar–Apr 2021 | 100 (39) | 160 (52) | 53 (17) | 81 (20) | 12 (4) | 7 (3) | 3 (3) | 5 (2) | |||
May–Jun 2021 | 124 (35) | 230 (57) | 70 (18) | 123 (26) | 65 (22) | 88 (24) | 40 (15) | 70 (16) | |||
Jul–Aug 2021 | 68 (12) | 271 (32) | 59 (9) | 132 (20) | 34 (7) | 89 (15) | 44 (9) | 60 (13) | |||
Sep–Oct 2021 | 117 (19) | 775 (37) | 35 (11) | 410 (26) | 15 (5) | 180 (20) | 13 (6) | 156 (17) | |||
Nov–Dec 2021 | 25 (8) | 202 (25) | 77 (13) | 18 (5) | 174 (18) | 66 (14) | 15 (2) | 23 (8) | 2 (1) | 33 (5) | |
Jan–Feb 2021 | 38 (3) | 96 (8) | 49 (7) | 11 (2) | 50 (9) | 31 (7) | 2 (1) | 13 (2) | |||
Variants | Untyped | 413 (111) | 1262 (158) | 56 (9) | 221 (55) | 770 (94) | 71 (14) | 122 (36) | 272 (50) | 97 (30) | 256 (43) |
α, β, γ | 58 (16) | 78 (21) | 33 (8) | 49 (16) | 14 (5) | 10 (5) | 7 (2) | 8 (2) | |||
δ | 77 (23) | 380 (47) | 29 (10) | 30 (9) | 150 (25) | 12 (7) | 13 (7) | 109 (16) | 11 (5) | 60 (10) | |
ο | 21 (4) | 75 (16) | 41 (12) | 1 (1) | 21 (8) | 14 (8) | 1 (1) | 9 (4) | |||
Commercial vaccine | BNT162b2 | 341 (91) | 927 (137) | 52 (12) | 154 (36) | 458 (70) | 35 (8) | ||||
mRNA-1273 | 92 (29) | 504 (57) | 43 (9) | 48 (14) | 247 (39) | 19 (6) | |||||
ChAdOx1 | 144 (39) | 185 (40) | 108 (29) | 167 (28) | |||||||
Ad26.COV2.S | 187 (20) | 111 (18) | |||||||||
Sex | Men | 22 (12) | 60 (17) | 4 (2) | 4 (3) | 15 (7) | 2 (1) | 1 (1) | 3 (2) | 1 (1) | 5 (3) |
Women | 25 (14) | 51 (20) | 4 (2) | 4 (3) | 14 (7) | 2 (1) | 1 (1) | 3 (2) | 1 (1) | 5 (3) | |
Age | <18 years | 45 (8) | 98 (14) | 2 (2) | 12 (6) | 1 (1) | 14 (1) | ||||
18–65 years | 110 (29) | 430 (50) | 17 (5) | 76 (19) | 232 (40) | 20 (7) | 30 (10) | 108 (16) | 25 (9) | 77 (19) | |
>65 years | 105 (30) | 251 (51) | 8 (5) | 72 (22) | 221 (43) | 11 (7) | 31 (12) | 68 (17) | 35 (11) | 98 (22) | |
Comorbidities | Undetermined | 510 (123) | 1 680 (179) | 110 (19) | 241 (57) | 881 (104) | 81 (20) | 138 (40) | 385 (56) | 94 (32) | 296 (46) |
Specified | 59 (17) | 115 (31) | 16 (5) | 44 (16) | 109 (30) | 16 (6) | 12 (2) | 15 (8) | 21 (3) | 28 (8) | |
Population | General | 426 (69) | 1 520 (117) | 115 (17) | 254 (46) | 893 (88) | 87 (18) | 126 (28) | 372 (45) | 109 (29) | 309 (40) |
HCW | 101 (44) | 185 (51) | 8 (4) | 17 (2) | 18 (11) | 14 (10) | 6 (4) | 8 (5) | |||
HRG | 42 (21) | 90 (30) | 11 (3) | 23 (15) | 80 (25) | 10 (2) | 6 (2) | 14 (6) | 7 (4) | ||